Quarterly Financial Results and Development Program Updates - Research Report on Regeneron, DaVita, Celldex, Isis, and VIVUS

NEW YORK, August 9, 2013 /PRNewswire/ --

Today, Investors' Reports announced new research reports highlighting Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), DaVita HealthCare Partners Inc. (NYSE: DVA), Celldex Therapeutics, Inc. (NASDAQ: CLDX), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS), and VIVUS, Inc. (NASDAQ: VVUS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Regeneron Pharmaceuticals Inc. Research Report

On August 6, 2013, Regeneron Pharmaceuticals Inc. (Regeneron) reported its Q2 2013 financial results and provided an update on development programs. The Company's revenues increased 50.3% YoY to $457.6 million. Net income of $87.4 million or $0.79 per diluted share in Q2 2013, was higher as compared to net income of $76.7 million or $0.70 per diluted share in Q2 2012. Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron, said, "We are pleased with the continued progress of EYLEA both in terms of commercialization and development in additional indications." He added, "Today, we reported positive Phase 3 data for EYLEA from the VIVID-DME and VISTA-DME trials in diabetic macular edema (DME). Based upon discussions with the U.S. Food & Drug Administration, we now plan to submit a regulatory application for approval for EYLEA in the DME indication in the U.S. later this year, approximately one year ahead of our previous plan." The Full Research Report on Regeneron Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-06/REGN]

--

DaVita HealthCare Partners Inc. Research Report

On August 6, 2013, DaVita HealthCare Partners Inc. (DaVita) reported its Q2 2013 results. Total net revenues increased 50.1% YoY to $2.9 billion. Net income attributable to DaVita was $254.4 million or $2.37 per diluted share in Q2 2013, compared to $95.3 million or $0.99 per diluted share in Q2 2012. The Company also revised its consolidated operating income guidance for full-year 2013, and now expects it to be in the range of $1,830 million to $1,930 million, up from its previous guidance range of $1,800 million to $1,900 million. The Full Research Report on DaVita HealthCare Partners Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-06/DVA]

--

Celldex Therapeutics, Inc. Research Report

On August 6, 2013, Celldex Therapeutics Inc. (Celldex) reported its Q2 2013 financial results and provided updates on its development programs. The Company's total revenue declined 95.2% YoY to c.$0.1 million. Net loss was $19 million or $0.24 per diluted share in Q2 2013, compared to a net loss of $13.8 million or $0.23 per diluted share in Q2 2012. Anthony Marucci, President and Chief Executive Officer of Celldex, said, "In the second quarter, Celldex continued to advance multiple clinical programs towards key inflection points. We completed several important steps in preparation for the initiation of our accelerated approval study of CDX-011 in triple negative breast cancer, including selecting a diagnostic partner. We also remain pleased with the pace of enrollment in our Phase 3 study of rindopepimut in frontline glioblastoma and look forward to presenting data from our Phase 2 study in refractory glioblastoma at the Society for Neuro-Oncology meeting later this year. In addition, we enrolled the first patient in our pilot study of CDX-1135 in dense deposit disease and initiated expansion cohorts in our Phase 1 study of CDX-1127 in metastatic melanoma and renal cell carcinoma." The Full Research Report on Celldex Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-06/CLDX]

--

ISIS Pharmaceuticals, Inc. Research Report

On August 6, 2013, ISIS Pharmaceuticals, Inc. (Isis) reported its Q2 2013 financial results. The Company's total revenue decreased 19.5% YoY to $38 million. Net loss was $10.1 million or $0.09 per diluted share in Q2 2013, compared to a net loss of $1.2 million or $0.01 per diluted share in Q2 2012. B. Lynne Parshall, Chief Operating Officer of Isis, said, "We ended the quarter with a significantly improved financial position. We added a new partner, Roche, for one of our severe and rare disease programs. We advanced our broad pipeline of drugs, and we reported positive Phase 2 data from our drug, ISIS-APOCIIIRx. These data support our belief that antisense drugs can be safe and effective treatments for many different diseases. All of these activities have significantly contributed to our financial performance this year and the increase in value of our technology and our drugs in development."The Full Research Report on ISIS Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-06/ISIS]

--

VIVUS, Inc. Research Report

On August 6, 2013, VIVUS, Inc. (VIVUS) reported its Q2 2013 financial results.Net product revenue from sales of Qsymia, the first FDA-approved once daily combination therapy for the treatment of obesity, was $5.5 million in Q2 2013. The Company reported net loss of $55.5 million or $0.55 per diluted share, compared to a net loss of $24 million or $0.24 per diluted share in Q2 2012. VIVUS said that the increased net loss in Q2 2013 as compared to Q2 2012 is primarily attributable to increased selling, general and administrative expenses related to commercialization activities for Qsymia. The Full Research Report on VIVUS, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-06/VVUS]

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Investors' Reports